Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc. (PTPI)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Operating loss from continuing operations | -987,036 | -336,506 | 2,809,766 | NaN |
| Operating income from continuing operations | NaN | NaN | NaN | 3,732,489 |
| Change in fair value of warrant liability | NaN | -1,700 | -1,000 | -10,302,657 |
| Gain on asset disposition and vivus settlement | NaN | NaN | 0 | 6,973,302 |
| Employee stock-based compensation | NaN | NaN | 75,137 | 154,359 |
| Warrant issuance costs | NaN | 0 | 0 | 10,420,982 |
| Gain from assignment of subsidiaries and vivus settlement | NaN | 6,973,302 | NaN | NaN |
| Employee stock-based compensation | 120,319 | 304,634 | NaN | NaN |
| Prepaid expenses and other current assets | 15,124 | -36,326 | -12,140 | 74,457 |
| Accounts payable | 49,421 | -337,259 | -548,883 | 205,690 |
| Accrued expenses | 48,148 | -369,543 | 251,405 | 160,983 |
| Net cash used in operating activities - continuing operations | -784,272 | -933,544 | -1,133,924 | -2,675,913 |
| Net cash (used in) provided by operating activities - discontinued operations | NaN | 0 | 0 | -1,991,326 |
| Net cash used in operating activities | -784,272 | -933,544 | -1,133,924 | -4,667,239 |
| Proceeds from common stock and prefunded warrants, net | NaN | 0 | 0 | 8,503,018 |
| Redemption of series a preferred stock | NaN | 0 | 117,311 | 224,249 |
| Net cash provided by (used in) financing activities - continuing operations | NaN | 0 | -117,311 | 8,278,769 |
| Net cash provided by (used in) financing activities | NaN | 0 | -117,311 | 8,278,769 |
| Net increase (decrease) in cash | -784,272 | -933,544 | -1,251,235 | 3,611,530 |
| Cash and cash equivalents, beginning of period | 5,136,722 | 6,070,266 | 3,709,971 | NaN |
| Cash and cash equivalents, end of period | 4,352,450 | 5,136,722 | 6,070,266 | NaN |
| Cash and cash equivalents, end of period - continuing operations | 4,352,450 | 5,136,722 | NaN | NaN |